Literature DB >> 19480009

A high proportion of bone marrow T cells with regulatory phenotype (CD4+CD25hiFoxP3+) in Ewing sarcoma patients is associated with metastatic disease.

Peter Brinkrolf1, Silke Landmeier, Bianca Altvater, Christiane Chen, Sibylle Pscherer, Annegret Rosemann, Andreas Ranft, Uta Dirksen, Heribert Juergens, Claudia Rossig.   

Abstract

Immunosuppressive CD4+CD25(hi)FoxP3+ T cells (T(reg) cells) have been found at increased densities within the tumor microenvironment in many malignancies and interfere with protective antitumor immune responses. Osseous Ewing sarcomas (ESs) are thought to derive from a bone marrow (BM) mesenchymal cell of origin, and microscopic marrow involvement defines a subpopulation of patients at a high risk of relapse. We hypothesized that BM-resident T cells may contribute to a permissive milieu for immune escape of ESs. Using 6-color-flow cytometry, we investigated the pattern of immune cell subset distribution including NK cells, gammadelta T cells, central and effector memory CD8+ and CD4+ T cells as well as T cells with regulatory phenotype (T(reg) cells) in BM obtained at diagnosis from 45 primary or relapsed ES patients treated within standardized protocols. Although patients at relapse had an inverted CD4:CD8 T-cell ratio, neither CD8+ effector/memory T-cell subsets nor T(reg) cells significantly differed from patients at diagnosis. No significant associations of innate and effector/memory T-cell subpopulations with known risk factors were found, including age, gender, tumor site, primary metastases and histological tumor response. By contrast, T(reg) cells were found at significantly higher frequencies in patients with primary metastatic disease compared with localized ESs (5.0 vs. 3.3%, p = 0.01). Thus, increased BM T(reg) cells in patients with metastasized ES may reflect an immune escape mechanism that contributes to the development of metastatic disease. Immunotherapeutic strategies will have to adequately consider the regulatory milieu within areas of Ewing tumor-immune interactions.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19480009     DOI: 10.1002/ijc.24461

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  18 in total

Review 1.  Immunotherapy in pediatric malignancies: current status and future perspectives.

Authors:  Christian M Capitini; Mario Otto; Kenneth B DeSantes; Paul M Sondel
Journal:  Future Oncol       Date:  2014       Impact factor: 3.404

2.  Transgenic antigen-specific, HLA-A*02:01-allo-restricted cytotoxic T cells recognize tumor-associated target antigen STEAP1 with high specificity.

Authors:  David Schirmer; Thomas G P Grünewald; Richard Klar; Oxana Schmidt; Dirk Wohlleber; Rebeca Alba Rubío; Wolfgang Uckert; Uwe Thiel; Felix Bohne; Dirk H Busch; Angela M Krackhardt; Stefan Burdach; Günther H S Richter
Journal:  Oncoimmunology       Date:  2016-04-25       Impact factor: 8.110

Review 3.  Immunotherapeutic strategies for sarcoma: current perspectives.

Authors:  Xueyao Li; Gangyang Wang; Zhengdong Cai; Wei Sun
Journal:  Am J Transl Res       Date:  2020-12-15       Impact factor: 4.060

Review 4.  Immunotherapy in Sarcoma: Future Horizons.

Authors:  Melissa Burgess; Vikram Gorantla; Kurt Weiss; Hussein Tawbi
Journal:  Curr Oncol Rep       Date:  2015-11       Impact factor: 5.075

Review 5.  Immunotherapy: A New (and Old) Approach to Treatment of Soft Tissue and Bone Sarcomas.

Authors:  Michael J Nathenson; Anthony P Conley; Edward Sausville
Journal:  Oncologist       Date:  2017-09-21

6.  CD4+CD25hiCD127- Treg and CD4+CD45R0+CD49b+LAG3+ Tr1 cells in bone marrow and peripheral blood samples from children with neuroblastoma.

Authors:  Fabio Morandi; Sarah Pozzi; Sebastiano Barco; Giuliana Cangemi; Loredana Amoroso; Barbara Carlini; Vito Pistoia; Maria Valeria Corrias
Journal:  Oncoimmunology       Date:  2016-10-24       Impact factor: 8.110

7.  Decreased ratio of CD8+ T cells to regulatory T cells associated with decreased survival in dogs with osteosarcoma.

Authors:  B J Biller; A Guth; J H Burton; S W Dow
Journal:  J Vet Intern Med       Date:  2010-07-28       Impact factor: 3.333

8.  Overexpression and immunosuppressive functions of transforming growth factor 1, vascular endothelial growth factor and interleukin-10 in epithelial ovarian cancer.

Authors:  Chan-Zhen Liu; Li Zhang; Xiao-Hong Chang; Ye-Xia Cheng; Hong-Yan Cheng; Xue Ye; Tian-Yun Fu; Jun Chen; Heng Cui
Journal:  Chin J Cancer Res       Date:  2012-06       Impact factor: 5.087

Review 9.  Advances in therapy for pediatric sarcomas.

Authors:  Aaron Weiss; Jonathan Gill; John Goldberg; Joanne Lagmay; Holly Spraker-Perlman; Rajkumar Venkatramani; Damon Reed
Journal:  Curr Oncol Rep       Date:  2014       Impact factor: 5.075

10.  Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial.

Authors:  Hussein A Tawbi; Melissa Burgess; Vanessa Bolejack; Brian A Van Tine; Scott M Schuetze; James Hu; Sandra D'Angelo; Steven Attia; Richard F Riedel; Dennis A Priebat; Sujana Movva; Lara E Davis; Scott H Okuno; Damon R Reed; John Crowley; Lisa H Butterfield; Ruth Salazar; Jaime Rodriguez-Canales; Alexander J Lazar; Ignacio I Wistuba; Laurence H Baker; Robert G Maki; Denise Reinke; Shreyaskumar Patel
Journal:  Lancet Oncol       Date:  2017-10-04       Impact factor: 41.316

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.